Acetylon Pharmaceuticals Receives $14,600,000 Series B Round

  • Feed Type
  • Date
    6/29/2011
  • Company Name
    Acetylon Pharmaceuticals
  • Mailing Address
    303 Congress Street 2nd Fl Boston, MA 02210
  • Company Description
    Acetylon Pharmaceuticals is a Boston-based company recently formed to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives.
  • Website
    http://www.acetylon.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $14,600,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will be used in part to fund the advancement of the Company’s lead drug candidate ACY-1215 – a next-generation Class II-selective histone deacetylase (HDAC) inhibitor – into Phase I/II clinical testing for patients with relapsed and relapsed-refractory multiple myeloma. This funding is part of a $27 million series B financing round.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy